ATE132755T1 - Mycobacterium vaccae in der behandlung von uveitis - Google Patents

Mycobacterium vaccae in der behandlung von uveitis

Info

Publication number
ATE132755T1
ATE132755T1 AT91919487T AT91919487T ATE132755T1 AT E132755 T1 ATE132755 T1 AT E132755T1 AT 91919487 T AT91919487 T AT 91919487T AT 91919487 T AT91919487 T AT 91919487T AT E132755 T1 ATE132755 T1 AT E132755T1
Authority
AT
Austria
Prior art keywords
uveitis
treatment
mycobacterium vaccae
vaccae
mycobacterium
Prior art date
Application number
AT91919487T
Other languages
English (en)
Inventor
Graham Arthur William Rook
Bumpstead
John Lawson Stanford
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London filed Critical Univ London
Application granted granted Critical
Publication of ATE132755T1 publication Critical patent/ATE132755T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Glass Compositions (AREA)
AT91919487T 1990-11-08 1991-11-08 Mycobacterium vaccae in der behandlung von uveitis ATE132755T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909024320A GB9024320D0 (en) 1990-11-08 1990-11-08 Treatment of uveitis

Publications (1)

Publication Number Publication Date
ATE132755T1 true ATE132755T1 (de) 1996-01-15

Family

ID=10685074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919487T ATE132755T1 (de) 1990-11-08 1991-11-08 Mycobacterium vaccae in der behandlung von uveitis

Country Status (10)

Country Link
EP (1) EP0556241B1 (de)
JP (1) JP3107568B2 (de)
AT (1) ATE132755T1 (de)
AU (1) AU665177B2 (de)
CA (1) CA2095854C (de)
DE (1) DE69116377T2 (de)
DK (1) DK0556241T3 (de)
GB (1) GB9024320D0 (de)
GR (1) GR3018652T3 (de)
WO (1) WO1992008484A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1038390C (zh) * 1993-03-20 1998-05-20 张锦铭 灭活卡介苗组合物
CA2164298A1 (en) 1993-06-04 1994-12-22 Richard A. Young Stress proteins and uses therefor
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
ES2266652T3 (es) 1997-08-05 2007-03-01 Stressgen Biotechnologies Corporation Respuestas inmunologicas contra los antigenos de hpv provocadas por compuestos que contienen un antigeno de hpv y una proteina de stress o un vector de expresion capaz de expresar dichas proteinas.
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
EP1054683B1 (de) 1998-02-20 2007-04-11 University Of Miami Modifizierter hitzeschockprotein/peptidantigen komplex
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
AU1814101A (en) 2000-01-14 2001-07-24 Massachusetts Institute Of Technology In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete ATP binding domain and is CD4+ cell-independent
AU6669401A (en) 2000-06-02 2001-12-11 Univ Connecticut Health Ct Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
CZ20024154A3 (cs) 2000-06-26 2003-08-13 Stressgen Biotechnologies Corporation Použití prostředku obsahujícího napojený protein pro výrobu farmaceutického přípravku pro léčení bradavic a chorob a stavů souvisejících s papiloma virem
RU2295536C2 (ru) 2001-02-05 2007-03-20 Стрессджен Байотекнолоджиз Корп. Композиции на основе белка вируса гепатита в и стрессового белка и их применение
CA2451026C (en) 2001-06-22 2013-12-10 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
EP2196473A1 (de) 2001-07-04 2010-06-16 Health Protection Agency Während der Latenz exprimierten Antigene aus Mycobacterium
US7666581B2 (en) 2001-08-20 2010-02-23 University Of Connecticut Health Center Methods for preparing compositions comprising heat shock proteins useful for the treatment of cancer and infectious disease
US20060251739A1 (en) * 2005-05-04 2006-11-09 National Yang-Ming University Composition and method for treating autoimmune disease and mucosal disorder
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
KR20110017356A (ko) 2008-03-20 2011-02-21 유니버시티 오브 마이애미 열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법
ES2845727T3 (es) 2015-02-06 2021-07-27 Heat Biologics Inc Vector que coexpresa una vacuna y moléculas coestimuladoras
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
NL8701163A (nl) * 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
GB8917256D0 (en) * 1989-07-28 1989-09-13 Univ London Biological preparation and its use
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
WO1992008484A1 (en) 1992-05-29
CA2095854C (en) 2003-08-19
GB9024320D0 (en) 1990-12-19
JP3107568B2 (ja) 2000-11-13
DK0556241T3 (da) 1996-02-12
AU8864491A (en) 1992-06-11
DE69116377T2 (de) 1996-05-30
GR3018652T3 (en) 1996-04-30
EP0556241B1 (de) 1996-01-10
JPH06501478A (ja) 1994-02-17
DE69116377D1 (de) 1996-02-22
AU665177B2 (en) 1995-12-21
CA2095854A1 (en) 1992-05-09
EP0556241A1 (de) 1993-08-25

Similar Documents

Publication Publication Date Title
DE69116377D1 (de) Mycobacterium vaccae in der behandlung von uveitis
ATE31670T1 (de) Verfahren zur behandlung von verpackungsmaterial und das dementsprechend behandelte material.
DE3483040D1 (de) Maschinelesbares dokument und dessen behandlung.
DE68909219D1 (de) Behandlung von obesitas.
DE69001458D1 (de) Mit einer benzotriazolgruppe substituierte diorganopolysiloxane enthaltende kosmetika sowie deren verwendung zum schutz von haut und haaren.
BG39294A3 (bg) Метод за получаване на карбоксиалкилни дипептиди
DE69113924D1 (de) Gravierverfahren von Gegenständen in fester Form und die hergestellten Gegenstände.
ATE192046T1 (de) Mycobacterium vaccae zur behandlung von lang andauernden autoimmunerkrankungen
ATE974T1 (de) Mittel und verfahren zur behandlung und verbesserung des aussehens von textilien.
CA2186851A1 (en) Use of mycobacteria for the treatment of tumours
JPS56100710A (en) Hair permanent treatment and composition therefor
RU93004600A (ru) Применение mycobacterium vaccae, способ лечения, продукт m vaccae, иммунотерапевтический агент
DE58901593D1 (de) Verfahren und einrichtung zur thermischen behandlung von abfallstoffen.
FI920356A0 (fi) En biologisk preparation samt dess anvaendning.
DE3850433D1 (de) Allergiebehandlung und Zusammensetzung dafür.
DE69034166D1 (de) Azellulärer Impfstoff
DK161320C (da) Analogifremgangsmaade til fremstilling af 2,3-diaryl-5-halogen-thiophener
ES2028069T3 (es) Articulo y metodo para cubrir un objeto.
ATE139259T1 (de) Selbstantigen der primären lebercirrhose
DE59008012D1 (de) Mittel zur Behandlung von Leder und Pelzen.
ATE81455T1 (de) (s)-emopamil zur anwendung bei der behandlung von migraene.
BG30021A3 (bg) Метод за получаване на имидазоизохинолин-диони
IT1103459B (it) Dispositivo e procedimento per l'impianto di capelli
DE3765583D1 (de) Oberflaechenbehandlungsmittel und -verfahren.
ATE53374T1 (de) Verfahren und mittel zur bekaempfung der kaffeeminiermotte, insbesondere der art perileucoptera coffeella.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee